HK Stock Market Move | MEDBOT-B(02252) rose more than 3% against the market trend, with strong company order trends and potential benefits from the rapid expansion of Siasun Robot & Automation at home and abroad.

MEDBOT-B (02252) rose more than 3% against the market trend. As of press time, it had risen by 3.27% to HK$22.1, with a turnover of HK$166 million. JP Morgan released a research report stating that MEDBOT-B has a strong order trend and is an important subsidiary under MICROPORT. It is expected that due to the rapid expansion of installations by Siasun Robot & Automation in China and overseas, the former's contribution to group sales will increase from approximately 3% in 2024 to around 40% in 2033. The bank reiterated its positive outlook on MICROPORT, describing it as a diversified local leader in the small and medium-sized medical technology field (SMID), with strong innovation capabilities, overseas market expansion, and expected profitability by 2026. It also noted that the group remains its top choice in the SMID medical technology field. CITIC SEC pointed out that the drive control system is one of the core universal components of the humanoid Siasun Robot & Automation power system. Domestic and foreign integrated machine manufacturers have successively introduced and preliminarily applied humanoid Siasun Robot & Automation products, and 2025 is expected to become the year of mass production for humanoid Siasun Robot & Automation. Against this background, most domestic general control enterprises have already begun to layout in some areas of humanoid Siasun Robot & Automation, suggesting to pay attention to the incremental opportunities brought by the humanoid Siasun Robot & Automation field for general control enterprises.